Trial Profile
Phase 1-2 Study of Onapristone in Patients With Progesterone Receptor Expressing Cancers
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Onapristone (Primary) ; Onapristone (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Endometrial cancer; Ovarian cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Arno Therapeutics
- 01 Jul 2020 Results presented in the Context Therapeutics Media Release.
- 27 Jun 2020 Results assessing safety of Onapristone Extended Release with emphasis on Hepatotoxicity published in the Drug Safety
- 31 May 2019 Results of pooled analysis of this and NCT02049190 assessing safety of onapristone in patients with metastatic cancer, published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).